* If you want to update the article please login/register
About 12 months after diagnosis of pleural mesothelioma, the mean survival rate is about 12 months. With 85-90% of patients classified as unresectable at diagnosis, the majority of patients present with stage III or IV disease. Patients receiving chemotherapy for peritoneal mesothelioma have a longer prognosis than pleural mesothelioma; however, patients undergoing chemotherapy for peritoneal mesothelioma have few well-studied treatment options due in large part to the disease's rarity. Mesothelin is also present in several cancers, including pancreatic, biliary adenocarcinomas, gastric, and ovarian cancers, in a significantly larger amount of thymic carcinoma than thymoma; mesothelin is also present in a substantial proportion of thymic carcinoma than thymoma. Improved overall survival in thymic cancer and decreased overall survival in patients with lung cancer have been correlated with reduced overall survival in patients with lung cancer. Patients will be monitored to determine the course of disease and record any treatment received for the eligible mesothelin expressing cancer.
Source link: https://clinicaltrials.gov/ct2/show/NCT01950572
To determine the possibility of focal stereotactic body radiation therapy with immune check inhibitors for mesothelioma therapy, click here. In patients treated with SBRT and ICI, acute and late toxicities can be determined overall. In Solid Tumors 1. 1 criteria, the objective response rate can be determined using the immune-modified Response Evaluation Criteria. Determine whether T-cell receptor expression changes during and after immunotherapy and SBRT, and whether these changes correlate with outcomes. Patients can also receive immunotherapy at the discretion of the treating medical oncologist.
Source link: https://clinicaltrials.gov/ct2/show/NCT04926948
Peplatinum is a drug that has been reported to be involved in small phase II studies in MPM. So, there is a need for novel therapeutic regimens with medications that may result in a synergistic reaction with penetolizumab. The aim of this research is to determine the potential clinical involvement, toxicity, and biomarkers of pesab-induced lenvatinib outcome in patients with recurrent MPM.
Source link: https://clinicaltrials.gov/ct2/show/NCT04287829
Response Evaluation Criteria in Solid Tumors To determine whether frontline treatment with carboplatin, pexed, bevacizumab, and atezolizumab has a higher response rate than carboplatin, peplatin, bevacizumab is better than carboplatin, pexed, and bevacizumab has a higher success rate than carboplatin, pesothelioma. To determine the safety of patients treated with palliative carboplatin, pexed, bevacizumab, and atezolizumab or carboplatin, pexed, bevacizumab, pexed, bevacizumab, and atezolizumab or carboplatin, pexed and bevacizumab, pexed and bevacizumab, pexed As determined by Positron Emission Tomography Response Criteria in Solid Tumors, researchers can determine whether frontline therapy with carboplatin, pexed, bevacizumab, and atezolizumab results in a higher metabolic response rate than carboplatin, pexed, bevacizumab results in a higher metabolic response rate than bevacizumab. Due to the outrage, determine the number of patients with unresectable disease who are able to undergo surgery after treatment with carboplatin, pegyed, bevacizumab, and atezolizumab. On day 1, patients are given atezolizumab intravenously over 60 minutes, bevacizumab IV over 30 minutes, carboplatin IV over 30 minutes, and pexed IV over ten minutes. In the absence of disease progression or unacceptable toxicity, patients who are not able to recover from surgery can receive atezolizumab and bevacizumab. On day 1, patients are treated to bevacizumab IV over 30-90 minutes, carboplatin IV over 30 minutes, and pexed IV over ten minutes. Bevacizumab with or without atezolizumab may be used by the investigator at the discretion of the investigator in the absence of disease progression or unacceptable toxicity. Patients underwent computed tomography scan and positron emission tomography scan as part of the investigation. Patients also undergo blood and tissue sample collection for the study.
Source link: https://clinicaltrials.gov/ct2/show/NCT05001880
The selection of a chemotherapeutic agent for HIPEC is largely based on primary tumor histology and provider preference rather than knowledge of the potential safety of a specific drug for an individual patient. Tissue responses to simulated ex vivo HIPEC therapy in the SMART System could help with chemotherapeutic agent selection for subsequent cytoreduction and intra-operative in vivo HIPEC therapies.
Source link: https://clinicaltrials.gov/ct2/show/NCT04847063
Despite potentially curative resections, malignant pleural mesotheliomoes are serious tumors with a strong tendency toward intrapleural recurrences. Patients with lung and esophageal cancers, digestive, pancreatic, and ovarian carcinomas, as well as sarcomas, are morbidity and mortality in patients with lung and esophageal carcinomas, gastrointestinal, pancreatic, and ovarian carcinomas, as well as sarcomas. Mesothelin is a popular target for cancer therapy due to its small number of receptors in normal human tissues and effects on cancer cell invasion and metastasis. The LMB-100 is a novel recombinant anti-mesothelin immunotoxin with a humanized fragment of an anti-mesothelin Fab conjugated to a de-immunized Pseudomonas exotoxin A with broad availability against cancer lines and tumor xenografts expressing mesothelin. In a murine model of minimal residual disease, the local government of LMB-100 can eliminate low-volume carcinomatosis in a murine model of minimal residual disease. Following cytoreductive surgery, Conceivably, intravitary administration of LMB-100 following cytoreductive surgery may increase local control of mesothelin-based malignancies that indicate mesothelin while minimizing systemic exposure of the immunotoxin. Primary Objective - To determine maximum tolerated dose and determine the toxicities of LMB-100 administered by 90-minute normothermic, intrapleural perfusion in participants with mesothelin-positive MPM or MPE from cancers that express mesothelin. Metastases of the central nervous system are rare. Participants with MPM and pleural effusions from other malignances will be included in the MTD, which will help identify toxicities, epidemiize time to disease progression, and overall survival by increasing enrollment.
Source link: https://clinicaltrials.gov/ct2/show/NCT05375825
Atezolizumab has been approved in the United States, European Union, and Switzerland for the treatment of NSCLC, urothelial carcinoma, small cell lung cancer, triple-negative breast cancer, and hepatocellular carcinoma patients. Patients with malignant pleural mesotheliothelioma and non-small cell lung cancer are not cured with available therapies, and will eventually relapse. Preclinical in vitro trials have shown a synergism of immunotherapy with PD1-targeted monoclonal antibodies and gemcitabine administered in a variety of tumor models, as well as ongoing clinical trials, which have provided promising results. Patients will be treated with gemcitabine 1000 mg/m2 i. v. (i. v. ) i. v. On day 1 and day 8 of each cycle, and with atezolizumab 1200 mg i. v. , they were able to perform properly. Starting with chemotherapy, the follow-up phase will last up to five years. The primary aim of this trial is to determine the safety of chemotherapy mixed with immunotherapy in patients with progressive NSCLC and MPM.
Source link: https://clinicaltrials.gov/ct2/show/NCT04480372
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions